Although early rodent studies raised concerns about thyroid cancer risk, the expanding body of human evidence on GLP-1 therapy and thyroid cancer risk offers increasing reassurance
Conclusion GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications
We always prioritize building for Ro patients, they are paying us for their health care and deserve our singular focus
Total T3 levels often decline during caloric restriction as the body downregulates metabolic rate to conserve energy, a process sometimes called "euthyroid sick syndrome" or "low T3 syndrome." Free T3 may remain in the normal range but trend toward the lower end
The combination of proper dosing frequency, careful tracking, and evidence-based adjustments produces the best outcomes
Redox Biol 12:854-863
